Frontlight ResearchEarly access
Not yet recruitingPhase 3
The REFINE study
Key facts
- Who runs it
- Karolinska University Hospital
- Where
- Sweden6 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 3
- People taking part
- 30 people, planned
- Started
- 30 Sept 2025
- Expected to end
- 31 Dec 2030
- Type of study
- Interventional
- Record updated
- 17 October 2025
Who can take part
- Age
- 18 years to 64 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- The subject has given their written consent to participate in the trial
- Autoimmune POI (FSH > 25 IU/L) including the presence of oligo/amenorrhea lasting at least 4 months, and elevated FSH levels (FSH > 25 IU/L) confirmed on two separate occasions, with measurements taken at least 4 weeks apart and Addison’s disease or ab positivity for 21-hydroxylase or other relevant autoantibodies (SCC, 17-OH, NALP5)
- 18-38 years of age
- Body mass index between 19-30
- Willing to use effective non-hormonal contraceptive method (such as intra uterine device (IUD), sexual abstinence, male or female condom with or without spermicide, cap, diaphragm or sponge with spermicide) during the 18-month study period
Who cannot take part
- Hormone replacement therapy within four weeks prior study entry
- Concurrent treatment with other immunosuppressive drugs
- Any vaccination within 4 weeks of infusion of study medication
- Any condition or any circumstance that in the opinion of the investigator would make it unsafe to undergo treatment with rituximab or controlled ovarian hyperstimulation
- Hypersensitivity to rituximab, any of the AxMPs, or any of the excipients (as detailed in the SmPC for the various IMPs)
- Vaginal bleeding of unknown etiology
- Active hepatitis B infection
- Active thrombolic disorder (contraindicated for Ovirelle)
- Moderate or severe impairment of kidney or liver function (contraindicated for Orgalutran)
- Severe psychiatric disorder
- Active, severe infection or JCV positivity
- Severe cardiac disease
- Cancer
- Benign tumours of the hypothalamus, pituitary, or ovarian pathology
- Pregnant or lactating women
- Severe immunosuppression
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The primary objective of this trial is to investigate the efficacy of rituximab in enabling egg retrieval after controlled ovarian hyperstimulation in autoimmune POI 4 to 6 months after rituximab compared to placebo, as well as the whole group treated with rituximab at 4 to 6 and 12 months after the last treatment session compared to baseline.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Immunomodulatory therapy to restore ovarian function and improve fertility in women with autoimmune premature ovarian insufficiency – a double-blind, placebo-controlled, randomized study
- Criteria questions
- Built from 2025-522133-66-00, who can take part
- Record updated
- 17 October 2025